MCID: TRD006
MIFTS: 59

Tardive Dyskinesia

Categories: Rare diseases, Neuronal diseases, Oral diseases

Aliases & Classifications for Tardive Dyskinesia

MalaCards integrated aliases for Tardive Dyskinesia:

Name: Tardive Dyskinesia 57 76 53 54 29 73
Neuroleptic-Induced Tardive Dyskinesia 73
Lingual-Facial-Buccal Dyskinesia 73
Drug-Induced Tardive Dyskinesia 73
Linguofacial Dyskinesia 53
Tardive Oral Dyskinesia 53
Tardive Dystonia 53
Td 53

Characteristics:

OMIM:

57
Inheritance:
autosomal recessive predisposition


HPO:

32
tardive dyskinesia:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 57 272620
MedGen 42 C0686347
SNOMED-CT via HPO 69 258211005 88425004

Summaries for Tardive Dyskinesia

NIH Rare Diseases : 53 Tardive dyskinesia is a neurological movement disorder that is caused by the long-term use of a certain type of medications called neuroleptics. Neuroleptic drugs are usually prescribed for psychiatric conditions, although they may be used to treat gastrointestinal or neurological conditions in some cases. Tardive dyskinesia is primarily characterized by repetitive involuntary movements of the jaw, lips and tongue such as grimacing; sticking out the tongue; and smacking, puckering and pursing the lips. Some affected people may also experience involuntary rapid, jerking movements (chorea) or slow, writhing movements (athetosis) of the arms and/or legs. It is unclear why some people who take neuroleptic medications develop these symptoms while others do not. Treatment for this condition varies but may include stopping or minimizing the use of neuroleptic drugs and/or taking additional medications to to reduce the severity of the symptoms.

MalaCards based summary : Tardive Dyskinesia, also known as neuroleptic-induced tardive dyskinesia, is related to bipolar i disorder and mood disorder, and has symptoms including spasmodic torticollis and myoclonus. An important gene associated with Tardive Dyskinesia is NQO1 (NAD(P)H Quinone Dehydrogenase 1), and among its related pathways/superpathways are Glucose / Energy Metabolism and Monoamine GPCRs. The drugs Aripiprazole and Chlorpromazine have been mentioned in the context of this disorder. Affiliated tissues include tongue, brain and eye, and related phenotypes are abnormality of the nervous system and tardive dyskinesia

OMIM : 57 Tardive dyskinesia is a debilitating motor disorder manifest as hyperkinetic, involuntary, repetitive movements predominantly of the orofacial region. It is a complication of treatment with so-called typical antipsychotic or neuroleptic agents, such as chlorpromazine or haloperidol, and is estimated to occur in 20 to 30% of chronic schizophrenics on long-term treatment (Thelma et al., 2008). (272620)

NINDS : 54 Tardive dyskinesia is a neurological syndrome caused by the long-term use of neuroleptic drugs. Neuroleptic drugs are generally prescribed for psychiatric disorders, as well as for some gastrointestinal and neurological disorders. Tardive dyskinesia is characterized by repetitive, involuntary, purposeless movements. Features of the disorder may include grimacing, tongue protrusion, lip smacking, puckering and pursing, and rapid eye blinking. Rapid movements of the arms, legs, and trunk may also occur. Involuntary movements of the fingers may be present.

Wikipedia : 76 Tardive dyskinesia (TD) is a disorder that results in involuntary, repetitive body movements. This may... more...

Related Diseases for Tardive Dyskinesia

Diseases related to Tardive Dyskinesia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
# Related Disease Score Top Affiliating Genes
1 bipolar i disorder 29.0 COMT HTR2A
2 mood disorder 28.8 COMT DRD2 DRD3 HTR2A
3 schizoaffective disorder 28.5 COMT DRD2 DRD3 HTR2A
4 bipolar disorder 28.5 COMT DRD2 DRD3 HTR2A
5 major depressive disorder 28.0 COMT CYP2D6 DRD2 DRD3 HTR2A
6 schizophrenia 28.0 COMT CYP1A2 CYP2D6 DRD2 DRD3 HTR2A
7 drug induced dyskinesia 11.5
8 dystonia 10.5
9 delusional disorder 10.5 DRD2 DRD3
10 impulse control disorder 10.5 DRD2 DRD3
11 depression 10.4
12 galactorrhea 10.4 CYP2D6 DRD2
13 migraine without aura 10.3 DRD2 DRD3
14 schizophreniform disorder 10.3 COMT DRD2
15 neuroleptic malignant syndrome 10.3 CYP2D6 DRD2
16 opiate dependence 10.3 DRD2 DRD3
17 oppositional defiant disorder 10.2 COMT DRD2
18 alexithymia 10.2 COMT DRD2
19 gilles de la tourette syndrome 10.2
20 aging 10.2
21 opioid addiction 10.2 COMT DRD2
22 traumatic brain injury 10.2 COMT DRD2
23 antisocial personality disorder 10.2 COMT DRD2
24 amelogenesis imperfecta, type ib 10.1 CYP1A2 CYP2D6
25 gastroparesis 10.1 CYP2D6 DRD2
26 cocaine dependence 10.1 DRD2 DRD3
27 movement disease 10.1
28 neuronitis 10.1
29 tremor 10.1
30 female stress incontinence 10.1 CYP1A2 CYP2D6
31 toxicity or absent response to clozapine 10.1 COMT CYP1A2
32 brain injury 10.1 COMT DRD2
33 schizophrenia 5 10.0 DRD3 HTR2A
34 alzheimer disease 10.0
35 major affective disorder 2 10.0
36 major affective disorder 4 10.0
37 major affective disorder 5 10.0
38 major affective disorder 6 10.0
39 major affective disorder 8 10.0
40 major affective disorder 7 10.0
41 major affective disorder 9 10.0
42 alacrima, achalasia, and mental retardation syndrome 10.0
43 diabetes mellitus 10.0
44 dementia 10.0
45 hypothyroidism 10.0
46 substance dependence 10.0 CYP2D6 DRD2 DRD3
47 polysubstance abuse 10.0 COMT DRD2 DRD3
48 alcoholic psychosis 9.9 DRD2 HTR2A
49 periodic limb movement disorder 9.9 DRD2 HTR2A
50 drug-induced mental disorder 9.9 DRD2 HTR2A

Comorbidity relations with Tardive Dyskinesia via Phenotypic Disease Network (PDN): (show all 16)


Acute Cystitis Alzheimer Disease
Anxiety Bipolar Disorder
Decubitus Ulcer Deficiency Anemia
Dysthymic Disorder Esophagitis
Hypertension, Essential Hypothyroidism
Major Depressive Disorder Paranoid Schizophrenia
Parkinson Disease, Late-Onset Protein-Energy Malnutrition
Schizophrenia Schizophreniform Disorder

Graphical network of the top 20 diseases related to Tardive Dyskinesia:



Diseases related to Tardive Dyskinesia

Symptoms & Phenotypes for Tardive Dyskinesia

Symptoms via clinical synopsis from OMIM:

57
Neuro:
tardive dyskinesia
repetitive rapid body movements
chewing movements
oral-lingual-buccal dyskinesia
tongue darting
more
Misc:
complication of treatment with neuroleptic agents


Clinical features from OMIM:

272620

Human phenotypes related to Tardive Dyskinesia:

32
# Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 32 HP:0000707
2 tardive dyskinesia 32 HP:0040141

UMLS symptoms related to Tardive Dyskinesia:


spasmodic torticollis, myoclonus

MGI Mouse Phenotypes related to Tardive Dyskinesia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.8 COMT CYP1A2 DRD2 DRD3 HSPG2 HTR2A
2 cardiovascular system MP:0005385 9.63 DRD3 HSPG2 SOD2 COMT CYP1A2 DRD2
3 homeostasis/metabolism MP:0005376 9.5 COMT CYP1A2 DRD2 DRD3 HSPG2 NQO1
4 liver/biliary system MP:0005370 9.02 CYP1A2 DRD2 HSPG2 NQO1 SOD2

Drugs & Therapeutics for Tardive Dyskinesia

Drugs for Tardive Dyskinesia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
2
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
4
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1 132539-06-1 4585
5
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
6
Zolpidem Approved Phase 4 82626-48-0 5732
7
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
8
Galantamine Approved Phase 4 357-70-0 9651
9
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
10
Nicotine Approved Phase 4 54-11-5 942 89594
11
Ziprasidone Approved Phase 4,Phase 3 146939-27-7 60854
12
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
13
Haloperidol Approved Phase 4 52-86-8 3559
14 tannic acid Approved, Nutraceutical Phase 4
15 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Antidepressive Agents Phase 4
20 Antiemetics Phase 4,Phase 1
21 Antimanic Agents Phase 4
22 Autonomic Agents Phase 4,Phase 1
23 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
25 Gastrointestinal Agents Phase 4,Phase 1
26 Lithium carbonate Phase 4 554-13-2
27 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
29 Peripheral Nervous System Agents Phase 4,Phase 1,Phase 2
30 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Serotonin Uptake Inhibitors Phase 4,Phase 1
32 GABA Agents Phase 4
33 GABA Agonists Phase 4
34 GABA-A Receptor Agonists Phase 4
35 Hypnotics and Sedatives Phase 4
36 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1
37 sultopride Phase 4
38 Cholinergic Agents Phase 4,Phase 1,Phase 2
39 Cholinesterase Inhibitors Phase 4
40 Nootropic Agents Phase 4,Phase 3,Phase 2
41 Antidepressive Agents, Second-Generation Phase 4
42 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
43 Cytochrome P-450 Enzyme Inhibitors Phase 4
44 Dopamine Uptake Inhibitors Phase 4
45 Quetiapine Fumarate Phase 4,Phase 1 111974-72-2
46 Dopamine D2 Receptor Antagonists Phase 4,Phase 3
47 decanoic acid Phase 4
48 Haloperidol decanoate Phase 4
49
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
50 Omega 3 Fatty Acid Nutraceutical Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia Unknown status NCT00837707 Phase 4 aripiprazole
2 The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
3 Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features Unknown status NCT00202293 Phase 4 Olanzapine;Lithium;Chlorpromazine
4 Risperidone and Zotepine in the Treatment of Delirium Unknown status NCT00622011 Phase 4 Risperidone and Zolpidem for delirium
5 Tardive Dyskinesia and Cognitive Function Completed NCT00926965 Phase 4 amisulpride;Olanzapine;Conventional antipsychotics
6 Treatment of Tardive Dyskinesia With Galantamine Completed NCT00164242 Phase 4 Galantamine
7 Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia Completed NCT00621998 Phase 4 risperidone;olanzapine
8 Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia Completed NCT00114595 Phase 4 eicosapentaenoic acid
9 The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia Completed NCT00495352 Phase 4 Hihg-doseNRT, Low-dose NRT, bupropion
10 Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics Completed NCT00458211 Phase 4 ziprasidone
11 A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00206102 Phase 4 quetiapine fumarate;risperidone
12 Antipsychotic Discontinuation in Alzheimer's Disease Completed NCT00417482 Phase 4 risperidone
13 Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women Completed NCT01937234 Phase 4 Metoclopramide;Placebo
14 Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia Recruiting NCT03323437 Phase 4 Risperidone
15 Agents Intervening Against Delirium in Intensive Care Unit Recruiting NCT03392376 Phase 4 Haloperidol Injection
16 Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates Not yet recruiting NCT03495024 Phase 4 Varenicline
17 Addressing Involuntary Movements in Tardive Dyskinesia Completed NCT02291861 Phase 3 SD-809;Placebo
18 Aim to Reduce Movements in Tardive Dyskinesia Completed NCT02195700 Phase 2, Phase 3 SD-809;Placebo
19 A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02274558 Phase 3 NBI-98854;Placebo
20 Piracetam for Treatment Tardive Dyskinesia Completed NCT00190008 Phase 3 piracetam
21 Extract of Ginkgo Biloba and Tardive Dyskinesia Completed NCT00672373 Phase 3 Extract of Ginkgo Biloba (EGb-761 capsules);Placebo
22 Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02405091 Phase 3 NBI-98854
23 Levetiracetam Treatment of Tardive Dyskinesia Completed NCT00291213 Phase 3 levetiracetam;placebo
24 Xenazine in Late Dyskinetic Syndrome With Neuroleptics Completed NCT01543321 Phase 3 Tetrabenazine;Placebo
25 A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia Completed NCT00210769 Phase 3 paliperidone ER Oros
26 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3 Risperdal
27 Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type Completed NCT01438060 Phase 3 Aripiprazole (BMS-337039);Placebo
28 High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms Completed NCT00403546 Phase 3 Ziprasidone 80-160 mg/d;Placebo;Ziprasidone 160 mg/d
29 Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia Recruiting NCT03176771 Phase 2, Phase 3 MT-5199;Placebo
30 Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia Recruiting NCT03254186 Phase 2, Phase 3 Propranolol Hydrochloride;Placebo Oral Tablet
31 Reducing Involuntary Movements in Tardive Dyskinesia Active, not recruiting NCT02198794 Phase 3 SD-809;Placebo
32 D-Serine Treatment For Tardive Dyskinesia Active, not recruiting NCT01804920 Phase 2, Phase 3
33 Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia Enrolling by invitation NCT02736955 Phase 3 Valbenazine
34 Pyridoxal Kinase Activity in Tardive Dyskinesia Withdrawn NCT01908452 Phase 3 Pyridoxine
35 Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia Unknown status NCT00621634 Phase 2
36 Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia Unknown status NCT00331669 Phase 2
37 Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia Completed NCT01267188 Phase 2 NBI-98854
38 A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia Completed NCT02064010 Phase 2 SNC-102;Placebo
39 NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia Completed NCT01733121 Phase 2 NBI-98854;NBI-98854;Placebo
40 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) Completed NCT01688037 Phase 2 NBI-98854;NBI-98854;Placebo
41 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder Completed NCT01393600 Phase 2 NBI-98854;NBI-98854;Placebo
42 Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia Completed NCT00175955 Phase 2 Levetiracetam
43 Dysport for the Treatment of OMD Completed NCT01921270 Phase 1, Phase 2 Low Dose - AbobotulinumtoxinA
44 Heart Rate Variability in Response to Metformin Challenge Completed NCT02500628 Phase 2 Metformin
45 Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia Completed NCT00401089 Phase 1, Phase 2 Panax Ginseng
46 Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy Completed NCT01677377 Phase 2 Risperidone;RBP-7000
47 Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia Completed NCT01176721 Phase 2
48 A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication Not yet recruiting NCT03557931 Phase 2 ASP4345;placebo;risperidone;quetiapine;olanzapine;ziprasidone;aripiprazole;brexpiprazole;paliperidone;lurasidone
49 Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia Terminated NCT00917293 Phase 2 Pyridoxal 5'-Phosphate;Placebo
50 Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021 Terminated NCT02342548 Phase 2 20 mg BID of PF-02545920

Search NIH Clinical Center for Tardive Dyskinesia

Genetic Tests for Tardive Dyskinesia

Genetic tests related to Tardive Dyskinesia:

# Genetic test Affiliating Genes
1 Tardive Dyskinesia 29

Anatomical Context for Tardive Dyskinesia

MalaCards organs/tissues related to Tardive Dyskinesia:

41
Tongue, Brain, Eye, Heart, Globus Pallidus, Bone, Subthalamic Nucleus

Publications for Tardive Dyskinesia

Articles related to Tardive Dyskinesia:

(show top 50) (show all 789)
# Title Authors Year
1
Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia. ( 29433806 )
2018
2
Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies. ( 29427000 )
2018
3
Tardive dyskinesia responsive to deep brain stimulation. ( 29506398 )
2018
4
Effectiveness and Value of 2 Novel Treatments for Tardive Dyskinesia. ( 29913006 )
2018
5
What You Should Know About Tardive Dyskinesia: Screening, Causes, and New Treatment Options. ( 29505191 )
2018
6
Tardive dyskinesia: Epidemiology. ( 29433811 )
2018
7
Vesicular monoamine transporter type 2 inhibition can lead to effective and tolerable management of tardive dyskinesia. ( 29945944 )
2018
8
VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia. ( 29609698 )
2018
9
Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. ( 29557243 )
2018
10
Tardive Dyskinesia: Is Vitamin E Singing the Prostate Blues? ( 29701932 )
2018
11
Two New Drugs for Tardive Dyskinesia Hit the Market. ( 29369770 )
2018
12
Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia. ( 29667946 )
2018
13
Valbenazine as the first and only approved treatment for adults with tardive dyskinesia. ( 29338466 )
2018
14
Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. ( 29409162 )
2018
15
VMAT2 inhibitors for the treatment of tardive dyskinesia. ( 29433808 )
2018
16
Future directions in tardive dyskinesia research. ( 29433809 )
2018
17
Correction to: Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. ( 29524074 )
2018
18
Miscellaneous treatments for antipsychotic-induced tardive dyskinesia. ( 29552749 )
2018
19
The importance of clinical observation: A case of subtle tardive dyskinesia with paliperidone palmitate. ( 29338294 )
2018
20
Altered serum levels of glial cell line-derived neurotrophic factor in male chronic schizophrenia patients with tardive dyskinesia. ( 29901253 )
2018
21
Vitamin E for antipsychotic-induced tardive dyskinesia. ( 29341067 )
2018
22
Reprint of: Clinical management of tardive dyskinesia: Five steps to success. ( 29519687 )
2018
23
Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. ( 29795977 )
2018
24
Clinical risk factors for the development of tardive dyskinesia. ( 29439776 )
2018
25
Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia. ( 29663328 )
2018
26
Resting-state Brain Activity Changes Associated with Tardive Dyskinesia in Patients with Schizophrenia: Fractional Amplitude of Low-frequency Fluctuation Decreased in the Occipital Lobe. ( 29909076 )
2018
27
Cholinergic medication for antipsychotic-induced tardive dyskinesia. ( 29553158 )
2018
28
Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia. ( 29342497 )
2018
29
Anticholinergic medication for antipsychotic-induced tardive dyskinesia. ( 29341071 )
2018
30
Tardive Dyskinesia: Recognition, Patient Assessment, and Differential Diagnosis. ( 29570969 )
2018
31
Benzodiazepines for antipsychotic-induced tardive dyskinesia. ( 29352477 )
2018
32
Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskinesia Assessment Workshop. ( 29742330 )
2018
33
Calcium channel blockers for antipsychotic-induced tardive dyskinesia. ( 29578611 )
2018
34
Amisulpride Reexposure and Tardive Dyskinesia. ( 29403138 )
2018
35
Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia. ( 29896031 )
2018
36
Deuterium Tetrabenazine for Tardive Dyskinesia. ( 29341821 )
2018
37
Tardive dyskinesia: Out of the shadows. ( 29449008 )
2018
38
Successful Treatment of Severe Tardive Dyskinesia with Valbenazine, Including a Patient's Perspective. ( 29114100 )
2017
39
Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. ( 28812541 )
2017
40
Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. ( 28146614 )
2017
41
Adjunctive Melatonin for Tardive Dyskinesia in Patients with Schizophrenia: A Meta-Analysis. ( 28904507 )
2017
42
Scopolamine alleviates involuntary lingual movements: tardive dyskinesia or dystonia? ( 28919765 )
2017
43
A new class of VMAT-2 inhibitors for tardive dyskinesia. ( 28668670 )
2017
44
Tardive Dyskinesia ( 28846278 )
2017
45
Tardive dyskinesia: motor system impairments, cognition and everyday functioning. ( 28877766 )
2017
46
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. ( 28839340 )
2017
47
Aripiprazole-induced Tardive Dyskinesia in 13 Years Old Girl Successfully Treated with Biperiden: A Case Report. ( 28783940 )
2017
48
Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs. ( 28790021 )
2017
49
Valbenazine for the treatment of tardive dyskinesia. ( 28699794 )
2017
50
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder. ( 28839341 )
2017

Variations for Tardive Dyskinesia

Expression for Tardive Dyskinesia

Search GEO for disease gene expression data for Tardive Dyskinesia.

Pathways for Tardive Dyskinesia

Pathways related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1 12.11 CYP1A2 CYP2D6 NQO1 SOD2
2
Show member pathways
11.6 DRD2 DRD3 HTR2A
3
Show member pathways
11.33 CYP1A2 CYP2D6 NQO1
4
Show member pathways
11.26 COMT CYP1A2
5
Show member pathways
11.23 COMT CYP1A2 CYP2D6
6 11.19 CYP1A2 NQO1
7 11.18 CYP1A2 NQO1
8 11.05 CYP1A2 CYP2D6
9 10.95 NQO1 SOD2
10 10.78 DRD2 DRD3
11
Show member pathways
10.67 COMT CYP1A2 CYP2D6 NQO1
12
Show member pathways
10.66 COMT CYP1A2 NQO1
13 10.55 COMT NQO1

GO Terms for Tardive Dyskinesia

Cellular components related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.13 COMT DRD2 HTR2A
2 dendrite GO:0030425 8.92 COMT DRD2 HTR2A NQO1

Biological processes related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.98 CYP1A2 CYP2D6 NQO1 SOD2
2 aging GO:0007568 9.81 HTR2A NQO1 SOD2
3 response to organic cyclic compound GO:0014070 9.77 COMT CYP1A2 NQO1
4 response to ethanol GO:0045471 9.73 DRD2 DRD3 NQO1
5 xenobiotic metabolic process GO:0006805 9.71 CYP1A2 CYP2D6 NQO1
6 negative regulation of protein kinase B signaling GO:0051898 9.69 DRD2 DRD3
7 circadian regulation of gene expression GO:0032922 9.68 DRD2 DRD3
8 visual learning GO:0008542 9.68 DRD2 DRD3
9 release of sequestered calcium ion into cytosol GO:0051209 9.68 DRD2 HTR2A
10 response to cocaine GO:0042220 9.67 DRD2 DRD3
11 positive regulation of cytokinesis GO:0032467 9.67 DRD2 DRD3
12 response to morphine GO:0043278 9.67 DRD2 DRD3
13 negative regulation of blood pressure GO:0045776 9.66 DRD2 DRD3
14 response to amphetamine GO:0001975 9.66 DRD2 DRD3
15 arachidonic acid secretion GO:0050482 9.65 DRD2 DRD3
16 drug metabolic process GO:0017144 9.65 CYP1A2 CYP2D6
17 exogenous drug catabolic process GO:0042738 9.65 CYP1A2 CYP2D6
18 temperature homeostasis GO:0001659 9.64 DRD2 HTR2A
19 superoxide metabolic process GO:0006801 9.64 NQO1 SOD2
20 dopamine receptor signaling pathway GO:0007212 9.63 DRD2 DRD3
21 synaptic transmission, dopaminergic GO:0001963 9.62 DRD2 DRD3
22 negative regulation of protein secretion GO:0050709 9.62 DRD2 DRD3
23 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.61 DRD2 HTR2A
24 positive regulation of renal sodium excretion GO:0035815 9.61 DRD2 DRD3
25 removal of superoxide radicals GO:0019430 9.6 NQO1 SOD2
26 prepulse inhibition GO:0060134 9.58 DRD2 DRD3
27 oxidative demethylation GO:0070989 9.58 CYP1A2 CYP2D6
28 G-protein coupled receptor internalization GO:0002031 9.57 DRD2 DRD3
29 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.55 DRD2 DRD3
30 heterocycle metabolic process GO:0046483 9.52 CYP1A2 CYP2D6
31 drug catabolic process GO:0042737 9.51 CYP1A2 CYP2D6
32 monoterpenoid metabolic process GO:0016098 9.49 CYP1A2 CYP2D6
33 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.48 DRD2 DRD3
34 acid secretion GO:0046717 9.46 DRD2 DRD3
35 negative regulation of dopamine receptor signaling pathway GO:0060160 9.43 DRD2 DRD3
36 behavioral response to cocaine GO:0048148 9.43 DRD2 DRD3 HTR2A
37 response to histamine GO:0034776 9.4 DRD2 DRD3
38 alkaloid metabolic process GO:0009820 9.37 CYP1A2 CYP2D6
39 response to drug GO:0042493 9.35 COMT CYP1A2 DRD2 DRD3 HTR2A
40 regulation of dopamine secretion GO:0014059 9.33 DRD2 DRD3 HTR2A
41 regulation of locomotion involved in locomotory behavior GO:0090325 9.32 DRD2 DRD3
42 dopamine metabolic process GO:0042417 8.8 COMT DRD2 DRD3

Molecular functions related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.71 CYP1A2 CYP2D6 NQO1 SOD2
2 monooxygenase activity GO:0004497 9.48 CYP1A2 CYP2D6
3 oxygen binding GO:0019825 9.46 CYP1A2 CYP2D6
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.43 CYP1A2 CYP2D6
5 aromatase activity GO:0070330 9.37 CYP1A2 CYP2D6
6 dopamine binding GO:0035240 9.32 DRD2 DRD3
7 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.26 DRD2 DRD3
8 superoxide dismutase activity GO:0004784 9.16 NQO1 SOD2
9 dopamine neurotransmitter receptor activity GO:0004952 8.96 DRD2 DRD3
10 drug binding GO:0008144 8.92 CYP2D6 DRD2 DRD3 HTR2A

Sources for Tardive Dyskinesia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....